Kantarjian et al53 assessed the efficacy and safety of dasatinib, as when compared with imatinib, for the first-line treatment method of CML-CP. 5 hundred and nineteen patients with recently diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of one hundred mg when everyday (259 sufferers) or https://simondqerd.blogaritma.com/28366376/the-greatest-guide-to-iwr-1